Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and LymphGen genetic subtyping for the HOVON84 (n = 208, EudraCT-2006-005174-42) and PETAL (n = 204, EudraCT-2006-001641-33) trials retrospectively combined with DFCI genetic data (n = 304). For all R-CHOP treated patients (n = 592), C5/MCD- and C2/A53-subtypes show significantly worse outcome independent of the international prognostic index. For all subtypes, adverse prognostic value of i/eot-PET-positive status is confirmed....

BACKGROUND: High-dose methotrexate (HD-MTX)-based polychemotherapy is widely used for patients with central nervous system (CNS) lymphoma. The pharmacokinetic (PK) variability and unpredictable occurrence of toxicity remain major concerns in HD-MTX treatment. OBJECTIVES: This study aimed to characterize the population PK of HD-MTX in patients with CNS lymphoma and to identify baseline predictors and exposure thresholds that predict a high risk of nephro- and hepatotoxicity. METHODS: Routinely monitored serum MTX concentrations after intravenous infusion of HD-MTX and MTX dosing information were collected retrospectively. Acute event of toxicity (≥ grade...

Chimeric antigen receptor T-cell therapy (CART) has replaced salvage immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) as the preferred second-line treatment for early relapsed (< 12 months) large B-cell lymphoma (LBCL). However, for patients with a late relapse (> 12 months), CART is inaccessible until third line. We analyzed 877 patients from the HemoBase registry (diagnosed 2005-2020) to assess differences in long-term outcomes of early versus late relapse in second line. Early relapse occurred in 120/654 patients (18%) who completed first-line treatment, with 2- and 5-year overall survival...

The optimal treatment of patients with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) that underwent incomplete resection, have advanced stage disease or relapse after resection remains unknown. We describe the treatment and outcome of all 91 Dutch BIA-ALCL patients up to 2023. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Ann Arbor stage I was frequently encountered (74%) compared to stage II (13%) and stage IV (11%). First-line treatment of stage I patients consisted mostly of surgery (88%). Stage II patients were treated with chemotherapy (CT)...

Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of 15 different neoplasms in adults. In Europe and North America, PTCL not otherwise specified (PTCL NOS), nodal T follicular helper lymphoma, angioimmunoblastic type (nTFHL-AI), and anaplastic large cell lymphoma (ALCL) either anaplastic lymphoma kinase (ALK) positive (+) or negative (-) are the most prevalent PTCLs. Relapsed or refractory disease (R/R) is common in PTCL and its management is challenging. Despite response rates and prognoses being disease specific, the outcome of R/R PTCL is dismal except for R/R ALK+ ALCL....